AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02267538
Drug: dexmedetomidine hydrochloride for injection
RxNorm normalized name: Dexmedetomidine Hydrochloride
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Before anesthesia, dexmedetomidine hydrochloride for injection (200 ug/2 ml) will be diluted with normal saline to 50 ml (final dexmedetomidine concentration 4 ug/ml).~Before the induction of anesthesia, a loading dose will be administered by intravenous infusion at a rate of \[0.9\*kg\] ml/h for 10 minutes (i.e., dexmedetomidine 0.6 μg/kg in 10 minutes), followed by continuous infusion at a rate of \[0.1\*kg\] ml/h (i.e., dexmedetomidine at a rate of 0.4 μg /kg/h) until the end of surgery.~At the end of surgery, the infusion rate will be decreased to \[0.025\*kg\] ml/h (i.e., dexmedetomidine at a rate of 0.1 ug/kg/h) and continued until the end of mechanical ventilation after surgery.
Trial: NCT02267538
Drug: 0.9% sodium chloride for injection
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Before anesthesia, 0.9% sodium chloride for injection 50 ml will be prepared.~Before the induction of anesthesia, a loading dose will be administered by intravenous infusion at a rate of \[0.9\*kg\] ml/h for 10 minutes, followed by continuous infusion at a rate of \[0.1\*kg\] ml/h until the end of surgery.~At the end of surgery, the infusion rate will be decreased to \[0.025\*kg\] ml/h and continued until the end of mechanical ventilation after surgery.
Trial: NCT01112878
Drug: Sugar pill
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage form: capsule, by mouth~Dosage: not applicable~Frequency and Dosage:~* once in the preoperative holding area and once before discharge from PACU~* continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery.
Trial: NCT01112878
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosage form: capsule, by mouth~Dosage: 600 mg~Frequency and duration:~* once in the preoperative holding area and once before discharge from PACU~* continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery.
Trial: NCT01112878
Drug: Clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosage form: capsule, by mouth~Dosage: 0.2 mg~Frequency and duration:~* once in the preoperative holding area and once before discharge from PACU~* continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery.
Trial: NCT00851929
Drug: Ambrisentan
RxNorm normalized name: Ambrisentan
DrugBank: Ambrisentan (DB06403)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ambrisentan 5 mg/day for month month, then 10 mg/day for 3 additional months
Trial: NCT01714401
Drug: Salbutamol 5mg
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 min nebulization of 5 mg of salbutamol
Trial: NCT00675220
Drug: insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Trial: NCT00196872
Drug: Epirubicine
RxNorm normalized name: Epirubicine
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epirbubicne is given
Trial: NCT00196872
Drug: Taxol
RxNorm normalized name: Taxol
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Taxol is given
Trial: NCT00196872
Drug: Xeloda
RxNorm normalized name: Xeloda
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Xeloda is given
Trial: NCT01809184
Drug: insulin 287
RxNorm normalized name: Insulin 287
DrugBank: Insulin icodec (DB16693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered insulin 287. The subjects will be dosed in the fasting state and receive one single dose followed by a 24-hour euglycaemic glucose clamp.
Trial: NCT01809184
Drug: insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine administered subcutaneously (s.c., under the skin) at fixed dose levels.
Trial: NCT02699801
Drug: propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: propofol for post-sternal closure sedation
Trial: NCT02699801
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: dexmedetomidine for post-sternal closure sedation
Trial: NCT01937325
Drug: ivacaftor
RxNorm normalized name: Ivacaftor
DrugBank: Ivacaftor (DB08820)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: active arm
Trial: NCT01165645
Drug: lopinavir
RxNorm normalized name: Lopinavir
DrugBank: Lopinavir (DB01601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT01165645
Drug: ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given orally
Trial: NCT03993912
Drug: Daratumumab SC in combination with Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daratumumab SC 1800 mg~* once every week for 8 weeks~* then once every other week for 16 weeks~* thereafter once every 4 weeks, until progression
Trial: NCT03993912
Drug: Lenalidomide PO (25mg)
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide PO (25mg): days 1 through 21 of each 28-day cycle, until progression
Trial: NCT03993912
Drug: Dexamethasone PO (20mg): days 1, 8, 15, 22 of each 28-day cycle, until progression
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone PO (20mg): days 1, 8, 15, 22 of each 28-day cycle, until progression
Trial: NCT04268563
Drug: metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: metformin tablet
Trial: NCT04268563
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sitagliptin tablet
Trial: NCT04268563
Drug: Sitagliptin/metformin
RxNorm normalized name: sitagliptin/metformin HCl 50 mg-500 mg ORAL TABLET
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sitagliptin/metformin tablet
Trial: NCT02771418
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous induction and maintenance of general anesthesia with propofol is a routine practice for this intervention
Trial: NCT02771418
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Volatile induction and maintenance of general anesthesia with sevoflurane is a generally acceptable clinical approach for this intervention
Trial: NCT01711918
Drug: Domperidone
RxNorm normalized name: Domperidone
DrugBank: Domperidone (DB01184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet; dose is 10mg per tablet given up to 3 times daily.
Trial: NCT00652860
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00652860
Drug: ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00652860
Drug: mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02042196
Drug: KUVAN
RxNorm normalized name: Kuvan
DrugBank: Sapropterin (DB00360)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: KUVAN will be given orally at 10mg/kg dose per body weight. KUVAN will be dissolved in 4-8oz water and consumed within 15 minutes.
Trial: NCT02042196
Drug: Cetrotide
RxNorm normalized name: Cetrotide
DrugBank: Cetrorelix (DB00050)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cetrotide (0.25mg/d) will be taken daily for 10 days via abdominal subcutaneous injection.
Trial: NCT02042196
Drug: Climara
RxNorm normalized name: Climara
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.075mg/d transdermal patch will be placed on skin.
Trial: NCT00604864
Drug: anti TNFa monoclonal antibody - Infliximab
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Chimeric A2 (infliximab, RemicadeTM) IgG ; 100 mg infliximab IgG, Infliximab was freshly prepared immediately before each administration. Infliximab or placebo was administered as a slow infusion of 250mL on weeks 0, 2 and 6. Women were closely observed during, and for 1 hour after, the infusion in the event of any serious adverse reactions.
Trial: NCT03875690
Drug: Injection of sodium chloride
RxNorm normalized name: Ocean brand of sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients in the placebo group will receive 50 mL of sodium chloride 0.9% in a ready-to-use bag during 30 minutes at anaesthesic induction.
Trial: NCT01849666
Drug: phenprocoumon
RxNorm normalized name: phenprocoumon
DrugBank: Phenprocoumon (DB00946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6 mg oral single dose
Trial: NCT01849666
Drug: vemurafenib
RxNorm normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 960 mg bid orally
Trial: NCT03442218
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal wash with saline solution previous to cesarean section in patients with premature rupture of membranes.
Trial: NCT01592864
Drug: Stannous Fluoride
RxNorm normalized name: Stannous Fluoride
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dentifice
Trial: NCT01592864
Drug: Sodium Monofluorophosphate
RxNorm normalized name: Sodium Monofluorophosphate
DrugBank: Sodium fluorophosphate (DB09484)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dentifrice
Trial: NCT03865147
Drug: Tri-Solfen Gel (Lidocaine HCl, Bupivacaine HCl, Adrenaline Acid Tartrate /Cetrimide)
RxNorm normalized name: cetrimide / lidocaine Topical Gel
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Investigational Drug
Trial: NCT03865147
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active Comparator
Trial: NCT03865147
Drug: Post Operative Analgesia (Paracetamol, Ibuprofen)
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care
Trial: NCT00114192
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00114192
Drug: thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02171325
Drug: irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60 mg/m2、65mg/m2、70mg/m2、75mg/m2、80mg/m2、85mg/m2、90mg/m2、95mg/m2、100mg/m2
Trial: NCT00001563
Drug: EPOCH
RxNorm normalized name: Epoch Blemish
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EPOCH-R every 3 weeks for up to 6 cycle
Trial: NCT03061630
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: D1.8.15 : GEMCITABINE 1000MG/M2
Trial: NCT03061630
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D1: CISPLATIN 60G/M2
Trial: NCT03008447
Drug: LEM5
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single dose of lemborexant 5 mg administered within 5 minutes before bedtime.
Trial: NCT00079092
Drug: procarbazine hydrochloride
RxNorm normalized name: Procarbazine Hydrochloride
DrugBank: Procarbazine (DB01168)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00079092
Drug: thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03008447
Drug: LEM10
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single dose of lemborexant 10 mg administered within 5 minutes before bedtime.
Trial: NCT02913196
Drug: Apalutamide
RxNorm normalized name: Apalutamide
DrugBank: Apalutamide (DB11901)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Orally available, small molecule, nonsteroidal potent and selective antagonist of the androgen receptor.~Cohort 1 dose: 120 mg QD Cohort 2 dose: 240 mg QD Cohort 3 dose: 180 mg QD
Trial: NCT02913196
Drug: Abiraterone acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Abiraterone acetate is the prodrug of the active drug abiraterone. Once absorbed after oral administration, abiraterone acetate is rapidly converted to the active form, abiraterone.~Dose: 1000 mg QD
Trial: NCT02913196
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Taxane cytotoxic chemotherapy with demonstrated survival benefit in those with advanced prostate cancer.~Dose: 75 mg/m2 Q3W
Trial: NCT03008447
Drug: ZOL
RxNorm normalized name: Zol
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single dose of zolpidem 6.25 mg administered within 5 minutes before bedtime.
Trial: NCT03008447
Drug: PBO
RxNorm normalized name: Zepbound
DrugBank: Tirzepatide (DB15171)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose of placebo administered within 5 minutes before bedtime.
Trial: NCT02913196
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose: 5 mg BID
Trial: NCT00372970
Drug: Botulinum toxin A
RxNorm normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: 200 U given by injection into the pylorus.
Trial: NCT00601640
Drug: Eflornithine HCL ointment
RxNorm normalized name: Eflornithine Hydrochloride
DrugBank: Eflornithine (DB06243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given topically twice daily on days 1-90
Trial: NCT00004870
Drug: irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02453360
Drug: Adductor Canal Block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed envelope with the group assignment designated within. All studied volumes are well within the acceptable range for SSACNB.
Trial: NCT04162522
Drug: Escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants are given escitalopram for 8 weeks. At week 8, those classified as responders will continue on escitalopram until the end of study.
Trial: NCT04162522
Drug: Brexpiprazole
RxNorm normalized name: Brexpiprazole
DrugBank: Brexpiprazole (DB09128)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants who are classified as non-responders are given 8 weeks add-on brexpiprazole, in addition to escitalopram, for the remainder of the study.
Trial: NCT03580980
Drug: Paracetamol and ketamine
RxNorm normalized name: codeine and paracetamol
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous paracetamol and ketamine followed by ketorolac
Trial: NCT03580980
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patient controlled analgesia by morphine
Trial: NCT00191230
Drug: gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00191230
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00191230
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00119587
Drug: darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02041338
Drug: Paclitaxel and carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02041338
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02041338
Drug: Epirubicin and Paclitaxel
RxNorm normalized name: paclitaxel and encequidar
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02720692
Drug: N1539
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02806960
Drug: Nasal Glucagon
RxNorm normalized name: glucagon Nasal Powder
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered intranasally.
Trial: NCT00039858
Drug: Argatroban
RxNorm normalized name: Argatroban
DrugBank: Argatroban (DB00278)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00508885
Drug: Niacinamide
RxNorm normalized name: Niacinamide
DrugBank: Nicotinamide (DB02701)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Niacinamide 250 mg twice daily titrated up to 750 mg twice daily
Trial: NCT00462189
Drug: CAT-8015 Immunotoxin
RxNorm normalized name: Spotted cat
DrugBank: Channel catfish (DB15548)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04607525
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: On the scheduled time of operation, the head nurse opened each envelope just before surgery, prepared the infusion solution and handled it to the anesthesiologist who was blinded to the solution. He was then determined for collecting perioperative data.~Group D: Patients received 0.5 µg/kg/h of Dexmedetomidine. Dexmedetomidine dosage was diluted in 50 ml syringe of normal saline Group C: Patients received equal volume and rate of normal saline as Group D.~This dosing regimen was in accordance with existing guidelines \[5\] \[6\] \[7\].
Trial: NCT02544282
Drug: Levobupivacaine
RxNorm normalized name: Levobupivacaine
DrugBank: Levobupivacaine (DB01002)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pecs II Block
Trial: NCT02544282
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: General Anesthesia
Trial: NCT02544282
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: General Anesthesia
Trial: NCT02544282
Drug: Atracurium
RxNorm normalized name: Atracurium
DrugBank: Atracurium besylate (DB00732)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: General Anesthesia
Trial: NCT02544282
Drug: Paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pain Relief
Trial: NCT02544282
Drug: Tramadol
RxNorm normalized name: Tramadol
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pain Relief
Trial: NCT02544282
Drug: Piritramide
RxNorm normalized name: piritramide
DrugBank: Piritramide (DB12492)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain Relief
Trial: NCT00092560
Drug: MK0653, ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00092560
Drug: Comparator: fenofibrate monotherapy
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03487211
Drug: Duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Duloxetine 30mg PO once daily for 1 week followed by an increase to 60mg PO once daily
Trial: NCT03487211
Drug: Escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Escitalopram 10mg PO once daily for 1 week followed by an increase to 20mg PO once daily
Trial: NCT00852228
Drug: IV cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab is administered every two weeks at the dose of 500 mg/m² over 2h30 (150 minutes).
Trial: NCT00335556
Drug: Irinotecan Hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01019317
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.5 grams/m\^2 over 2 hours(+/- 15 minutes) IV every 12 (+/-2) hours for 5 days (4 days in patients \> 65 years and 3 days in patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) \> 3).
Trial: NCT01019317
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/m\^2 to be given IV over 15-30 minutes every 12 (+/- 2) hours for 5 days. (4 days in patients \> 65 years and 3 days in patients with PS \> 3).
Trial: NCT00335556
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00335556
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV